CD19 and tuberculosis: The frequency of CD19+IgM+CD38+ and CD19+IgM−CD38+ cells expressing FASL/CD178 and IL5RA/CD125, as well as CD40 and PD1 were evaluated over the course of 6‐month anti‐TB treatment.